Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi SA (SNY) reports a robust 16% sales increase, driven by Dupixent and vaccines, while navigating market challenges and ...

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...